Reduction of neointimal hyperplasia in porcine coronary arteries by 2-deoxy-d-glucose

The drug eluting stents have been shown to play a substantial role in preventing in-stent restenosis. This study was initiated to determine the efficacy of 2-deoxy-d-glucose (2-DG) in an in-stent restenosis model for reducing neointimal hyperplasia after coronary stent placement. In a porcine overstretch model, three kinds of stents were investigated (n = 12 per group): bare metal stents (BMS), rapamycin-eluted stents (RES), and BMS after intracoronary short-term application of 2-DG (DGS). After 42 days histomorphometric and histopathological analyses were performed. Neointimal thickness (BMS: 0.38 +/- A 0.08, RES: 0.24 +/- A 0.11, DGS: 0.15 +/- A 0.01), area stenosis (BMS: 47.39 +/- A 2.76, RES: 32.2 +/- A 2.08, DGS: 29.30 +/- A 2.98) did not differ after 42 days between the RES and DGS but were significantly lower as compared to BMS only. Lumen area (BMS: 3.15 +/- A 1.53, RES: 4.37 +/- A 1.72, DGS: 4.77 +/- A 2.14) was significantly higher in the DGS group in comparison to the BMS group. The calculated injury and inflammation scores were similar and re-endothelialization was confirmed in all groups. This study could demonstrate that in porcine stent model neointimal hyperplasia and re-endothelialization after application of 2-DG are comparable to those seen in RES. Thus, 2-DG might be a promising clinical application for coronary stent coating.